Buy & Sell Nuvalent Inc (NUVL) – Nuvalent Inc Price Today
Aura AI Summary
Key Stats
- $8.32BMarket Cap
- TechnologySector
- -9.7%3M Drawdown
- $7.03BEnterprise Value
- -Dividend Yield
- 6 daysTypical Hold Time
Nuvalent Inc (NUVL) is currently valued at a market capitalization of $8.32B, with an enterprise value of $7.03B. Over the past 52 weeks, Nuvalent Inc has traded between a low of $69.85 and a high of $111.99, highlighting its annual price range. Over the past three months, Nuvalent Inc has recorded a drawdown of -9.7%, reflecting recent price volatility. On average, investors hold Nuvalent Inc for approximately 6 days, indicating typical investor behavior on the platform.
About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Most Recent News
Bernie Sanders warns Iran war costs could exceed $1 trillion, impacting every US household.
Senator Bernie Sanders criticized the Trump Administration's estimate that the Iran war would cost $25 billion, calling it misleading. He warned the actual cost could surpass $1 trillion, placing a heavy financial burden on American households. Sande...
Reaves Utility Income Fund targets rising electricity demand with 12% upside and 5% yield potential
The Reaves Utility Income Fund is an aggressive, actively managed fund focused on companies benefiting from increasing electricity demand, particularly driven by data center growth. The fund's portfolio aligns with top sector picks and shows potentia...
Mobia Medical shares fall 20% on IPO debut amid rising losses despite strong sales growth.
Mobia Medical went public but saw its shares drop over 20% on the first day, reflecting investor caution. The company’s Vivistim Paired VNS system targets the stroke recovery market, with revenues expected to double to $32 million by 2025. However, o...